ADMA Biologics Inc (NASDAQ:ADMA) Receives Average Recommendation of “Moderate Buy” from Brokerages

ADMA Biologics Inc (NASDAQ:ADMA) has received a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $18.6667.

A number of equities analysts have issued reports on ADMA shares. Raymond James Financial initiated coverage on ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price for the company. Zacks Research upgraded shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Finally, Mizuho cut their target price on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th.

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds have recently made changes to their positions in ADMA. Lido Advisors LLC lifted its stake in shares of ADMA Biologics by 3.8% in the fourth quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company’s stock worth $312,000 after acquiring an additional 629 shares during the period. Cim LLC lifted its position in shares of ADMA Biologics by 0.7% in the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock worth $1,341,000 after purchasing an additional 665 shares during the period. Smartleaf Asset Management LLC boosted its stake in shares of ADMA Biologics by 28.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 700 shares during the last quarter. Cerity Partners LLC increased its position in shares of ADMA Biologics by 1.8% during the second quarter. Cerity Partners LLC now owns 48,572 shares of the biotechnology company’s stock worth $884,000 after buying an additional 869 shares during the period. Finally, Legato Capital Management LLC increased its position in shares of ADMA Biologics by 4.7% during the fourth quarter. Legato Capital Management LLC now owns 30,895 shares of the biotechnology company’s stock worth $564,000 after buying an additional 1,374 shares during the period. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $9.45 on Thursday. The firm’s fifty day moving average price is $9.22 and its two-hundred day moving average price is $10.13. The stock has a market cap of $2.12 billion, a PE ratio of 13.50 and a beta of 0.78. ADMA Biologics has a fifty-two week low of $7.21 and a fifty-two week high of $20.46. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.81 and a current ratio of 6.97.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The company had revenue of $124.39 million during the quarter, compared to analysts’ expectations of $125.34 million. During the same period in the prior year, the company earned $0.14 EPS. ADMA Biologics’s revenue was up 2.0% compared to the same quarter last year. On average, equities analysts expect that ADMA Biologics will post 0.78 EPS for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.